Literature DB >> 8169752

Viral respiratory diseases in children: classification, etiology, epidemiology, and risk factors.

V G Hemming1.   

Abstract

The epidemiology, molecular structure, cell tropism, and pathophysiology of many human disease-causing viruses have been painstakingly and elegantly characterized during the past 50 years. Vaccines and antiviral drugs of varying efficacy were developed and tested. Despite the relegation of smallpox to a freezer chest and the progress in the control of measles and hepatitis B, the viruses that cause respiratory tract infections remain significant causes of illness and death in pediatric populations worldwide. This discussion surveys the virus groups that contain nearly 200 distinct viruses that cause sporadic and epidemic respiratory infections in children. The epidemiology of infection with the influenza A and B, parainfluenza, and respiratory syncytial viruses and adenoviruses and their impact on infants and children and the groups at highest risk for morbid outcomes are discussed.

Entities:  

Mesh:

Year:  1994        PMID: 8169752      PMCID: PMC7172644          DOI: 10.1016/s0022-3476(94)70185-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


Until the 1950s, little was known about the causes of acute upper respiratory tract infection or lower respiratory tract infection. It was evident that the bacterial causes of pneumonia, such as Streptococcus pneumoniae, Haemophilus influenzae, and the filterable agents responsible for swine and human influenza and measles, could not account for the majority of acute URTIs and LRTIs in children and adults. A real boom in respiratory virology came in the late 1950s and early 1960s, when markedly improved isolation and culture techniques and better serologic and biochemical methods were applied to the isolation and characterization of the viruses responsible for respiratory infections. Rhinoviruses, echoviruses, coxsackieviruses, adenoviruses, parainfluenza viruses, coronaviruses, and respiratory syncytial virus were added to influenza and measles viruses as causes of respiratory infections. Nearly 200 antigenically distinct viral agents were documented as causes of sporadic or epidemic URTI or LRTI in infants, children, and adults.

VIRUSES AND RESPIRATORY SYNDROMES

In 1963, Dr. Maxwell Finland chaired a symposium entitled "Problems in Definition of Respiratory Diseases and Respiratory Disease Agents." Papers presented by Dowling and Lefkowitz and by Parrott et al. defined the major clinical respiratory syndromes of adults and children and identified the major viruses responsible for these syndromes. Several respiratory syndromes were described in adults. The etiologic agents associated with these syndromes included coryza caused by rhinovirus, echovirus 28, and coxsackievirus A21; pharyngeal conjunctival syndrome caused by adenovirus; and pneumonia caused by influenza virus, para-influenza virus, adenovirus, and coxsackievirus. The clinical syndromes in infants and children described by Parrott et al. were derived from a cross-sectional analysis and the results of respiratory cultures collected between 1957 and 1961 from approximately 8000 children with respiratory infections. Croup syndromes were associated with parainfluenza viruses, RSV, adenoviruses, and influenza viruses. Bronchopneumonia was most likely caused by RSV, but it may also have been caused by parainfluenza viruses (particularly parainfluenza type 3), adenoviruses, influenza viruses, or Mycoplasma pneumoniae. A syndrome that the investigators called "bronchiolitic bronchopneumonia" was predominantly associated with RSV or parainfluenza type 3 infection. Severe bronchitis and pharyngitis were associated with RSV, adenoviruses, the parainfluenza viruses, and influenza viruses. Outpatient rhinitis, pharyngitis, and bronchiolitis were associated with the same agents that caused bronchiolitic bronchopneumonia. Table I summarizes current data on the common infectious pediatric respiratory syndromes and their usual causative agents. Little has changed in the three decades since the 1963 symposium. Indeed, although much more is known about etiology, pathogenesis, viral biochemistry, and genetics, the viruses described by the early 1960s continue to be responsible for present-day sporadic or epidemic respiratory infections in adults and children. It is not surprising that there is substantial clinical overlap. Respiratory tract infections may be caused by a variety of different viruses, and individual viruses can cause variable clinical syndromes.
Table I

Acute viral respiratory tract infections: Clinical syndromes and common causative viruses

Clinical syndromeAssociated viruses

Common coldRSV, PIVs, rhinovirus, coxsackieviruses, echoviruses, adenoviruses, coronaviruses

Laryngitis, tonsillitisAdenoviruses, Epstein-Barr virus

LaryngotracheobronchitisPIVs, influenza viruses, adenoviruses, rhinoviruses, RSV, measles

PneumoniaRSV, PIVs, adenoviruses, influenza viruses

PIVs, Parainfluenza viruses.

Acute viral respiratory tract infections: Clinical syndromes and common causative viruses PIVs, Parainfluenza viruses. A prospective long-term study to examine patterns of respiratory illnesses in an American community was initiated in Tecumseh, Mich., in 1965 by Monto et al.3, 4, 5, 6, 7, 8, 9, 10 This study surveyed representative segments of the Tecumseh population for respiratory infections from 1965 through 1971 and again from 1976 through 1981. The recovered viruses and the observed respiratory syndromes in nonhospitalized children and adults in Tecumseh mirrored the viruses and respiratory syndromes described by Parrott et al. Ultimately, more than 80 serotypes of rhinovirus were recovered from uncomplicated URTIs. In addition, RSV, parainfluenza viruses, influenza A and B, adenoviruses, and enteroviruses also were recovered from patients with URTI. The enteroviruses, however, were more likely to cause LRTI, to induce more severe illness, and to prompt reduction in normal activities and result in hospitalization, especially in the very young. In 1972, Loda et al. reported a study that examined the nature and cause of respiratory disease in infants and children during a 40-month period in a day care center. In this setting the observed clinical syndromes and recovered viruses were similar to those previously observed within the community, in outpatient settings, and among hospitalized children. The similarities included age-related incidence, seasonal occurrence, and illness association. In 1978 the National Institutes of Health held a workshop on the epidemiology of RSV and parainfluenza viruses. The observations made by several investigators at this workshop can be summarized as follows. Parainfluenza viruses types 1 and 2 alternated every other year; parainfluenza type 3 and RSV caused outbreaks of disease every winter. Approximately 40% to 50% of patients with croup yielded one of the parainfluenza viruses. Reinfections with RSV were common and caused less severe respiratory illness. Passively acquired maternal antibodies appeared to provide some protection for neonates. Nosocomial RSV infections were common in hospitalized children. Studies in Newcastle upon Tyne indicate that death rates in children with bronchiolitis were about 1% with RSV or parainfluenza pneumonia but approached 4% to 5% in infants with congenital heart disease. It was estimated that annually in the United States approximately 30,000 children were hospitalized with croup and an additional 12,000 children were hospitalized with RSV bronchiolitis or pneumonia. In 1978 Bulla and Hitze summarized data from the World Health Organization regarding the impact of acute respiratory infection on children (Table II). They reported 666,000 viral respiratory deaths in the 88 countries surveyed, which represented a total population of 1.2 billion. Mortality rates were highest in infants and were greatest in children of Central America, followed by those in Africa, South America, and Asia.
Table II

Mortality rates for acute respiratory infections in the world: 1970-1973 (rate per 100,000 population)

InfantsChildren aged 1-4 yrChildren aged 5-14 yr


Africa145446723

North America14683

Central America149514917

South America111111311

Asia82213218

Europe390152

Oceania61512112

Adapted from Bulla A, Hitze KL. Bull World Health Organ 1978;56:481-96.

Mortality rates for acute respiratory infections in the world: 1970-1973 (rate per 100,000 population) Adapted from Bulla A, Hitze KL. Bull World Health Organ 1978;56:481-96. A number of observations can be added to the 1978 National Institutes of Health workshop data describing etiologic agents, clinical syndromes, infection rates, and outcome of viral respiratory diseases throughout the world.14, 15, 16, 17, 18, 19, 20 Acute respiratory infections are common causes of death in young children worldwide. Viruses cause more than half of these acute infections. The morbidity and mortality rates from viral respiratory infections are much higher in developing countries. The viruses documented as being responsible for respiratory infections in developed countries (RSV, parainfluenza and influenza viruses, adenoviruses, enteroviruses, and rhinoviruses) also are responsible for infections in developing countries.

EPIDEMIOLOGY

Epidemiologic studies have attempted to determine the modes of transmission for respiratory viruses. It has long been presumed that infectious viruses are carried on particles or droplets that are expelled from the respiratory tracts of infected persons. This mode of transmission was considered responsible for virus spread among human beings; however, experimental data show this mode to be only marginally important. Rather, the most successful route of viral spread is by the transmission of infectious mucosal secretions to the fingers and hands, and subsequently to the nose or eyes of a susceptible recipient. The simple act of timely hand washing may be the most effective method of breaking the chain of transmission and thereby interrupting virus spread.21, 22, 23 Healthy infants, toddlers, and children are at high risk for encounter and infection with respiratory viruses. However, most will have a limited illness that will provoke the development of some immunity from subsequent infections with the same or similar agents. For most of the respiratory viruses, reexposure and reinfection are the rule.12, 24, 25, 26 Usually, reinfections cause less severe disease and are less likely to induce LRTIs that result in bronchiolitis or pneumonia. Several risk factors (Table III) increase the rates of infection and the resulting severity of disease. These factors include young age, low birth weight, prematurity, chronic cardiopulmonary disease, some congenital or acquired immunodeficiency disorders, malnutrition (especially with vitamin A deficiency), crowding, the number of children residing in the household, the presence of large numbers of susceptible people in the community, lack of breast-feeding, and exposure of the susceptible child to other infected persons. There is substantial evidence of increased susceptibility to and complications of infection in children exposed to polluted air, which includes secondhand smoke in the infant's residence.27, 28, 29
Table III

Risk factors influencing the incidence and severity of viral respiratory tract infection in infants and children

Age, immunologic experience

Prematurity, low birth weight

Chronic cardiopulmonary diseases

Immunodeficiency syndromes

Malnutrition

Exposure

Other children in family

Crowding

Care setting, family versus day care

Environmental pollution, parental smoking

Lack of breast-feeding
Risk factors influencing the incidence and severity of viral respiratory tract infection in infants and children Although vaccines for influenza A and B, RSV, parainfluenza virus type 3, and some adenoviral subtypes have been developed and tested,30, 31, 32 only the vaccines for influenza A and B currently are available and recommended for use in children. The primary reasons for the desultory progress in vaccine development are the large number of agents responsible for disease, the poor or unpredictable immunologic response to vaccination of susceptible infants and children, and the high development costs of potential limited-use vaccines.

SUMMARY

In summary, 80 years ago the treatment of choice for bronchiolitis and bronchopneumonia was 15-minute hot baths, as hot as the child could tolerate twice a day, or mustard packs, or both. Since then, viral respiratory diseases and their etiology, epidemiology, pathophysiology, and natural histories are understood much more extensively. However, specific prevention and effective treatments remain elusive. Still, many treatments of viral respiratory diseases are homeopathic or supportive. The authors of the following articles expand on these observations. They offer new information on improved methods that provide for the prevention and treatment of these exceedingly prevalent pediatric respiratory disorders.
  31 in total

1.  The Tecumseh study of respiratory illness. IV. Prevalence of rhinovirus serotypes, 1966-1969.

Authors:  A S Monto; J J Cavallaro
Journal:  Am J Epidemiol       Date:  1972-11       Impact factor: 4.897

2.  Respiratory disease in group day care.

Authors:  F A Loda; W P Glezen; W A Clyde
Journal:  Pediatrics       Date:  1972-03       Impact factor: 7.124

3.  The Tecumseh study of respiratory illness. 3. Incidence and periodicity of respiratory syncytial virus and Mycoplasma pneumoniae infections.

Authors:  A S Monto; S K Lim
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

4.  Immunity to and frequency of reinfection with respiratory syncytial virus.

Authors:  C B Hall; E E Walsh; C E Long; K C Schnabel
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Viral etiology and epidemiology of acute respiratory infections in children in Nairobi, Kenya.

Authors:  D T Hazlett; T M Bell; P M Tukei; G R Ademba; W O Ochieng; J M Magana; G W Gathara; E M Wafula; A Pamba; J O Ndinya-Achola
Journal:  Am J Trop Med Hyg       Date:  1988-12       Impact factor: 2.345

6.  Acute respiratory tract infections among a birth cohort of children from Cali, Colombia, who were studied through 17 months of age.

Authors:  I Borrero; L Fajardo; A Bedoya; A Zea; F Carmona; M F de Borrero
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

Review 7.  Viral vaccines for the prevention of childhood pneumonia in developing nations: priorities and prospects.

Authors:  M C Steinhoff
Journal:  Rev Infect Dis       Date:  1991 May-Jun

8.  The Tecumseh study of respiratory illness. I. Plan of study and observations on syndromes of acute respiratory disease.

Authors:  A S Monto; J A Napier; H L Metzner
Journal:  Am J Epidemiol       Date:  1971-09       Impact factor: 4.897

9.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

10.  Relationship of parental smoking to wheezing and nonwheezing lower respiratory tract illnesses in infancy. Group Health Medical Associates.

Authors:  A L Wright; C Holberg; F D Martinez; L M Taussig
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

View more
  12 in total

1.  Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function.

Authors:  D C Look; M J Walter; M R Williamson; L Pang; Y You; J N Sreshta; J E Johnson; D S Zander; S L Brody
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Use of monoclonal antibodies for rapid diagnosis of respiratory viruses in a community hospital.

Authors:  K E Irmen; J J Kelleher
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  Necrotizing adenoviral pneumonia: manifestation of nosocomial infection in pediatric intensive care unit.

Authors:  Pradeep Vaideeswar; S B Bavdekar; Sandhya M Jadhav; Rajiv Balan; Shobhana P Pandit
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

4.  Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study.

Authors:  B Gröndahl; W Puppe; A Hoppe; I Kühne; J A Weigl; H J Schmitt
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

5.  Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known?

Authors:  Patrícia Brito Rodrigues; Arilson Bernardo Dos Santos Pereira Gomes; Lívia Moreira Genaro; Lívia Bitencourt Pascoal; Ana Paula Duarte de Souza; Raquel Franco Leal; Marco Aurélio Ramirez Vinolo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Viral agents causing lower respiratory tract infections in hospitalized children: evaluation of the Speed-Oligo® RSV assay for the detection of respiratory syncytial virus.

Authors:  W Sánchez-Yebra; J A Ávila-Carrillo; F Giménez-Sánchez; A Reyes-Bertos; M Sánchez-Forte; M Morales-Torres; A Rojas; J Mendoza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-02       Impact factor: 3.267

7.  Multipathogen infections in hospitalized children with acute respiratory infections.

Authors:  Dan Peng; Dongchi Zhao; Jingtao Liu; Xia Wang; Kun Yang; Hong Xicheng; Yang Li; Fubing Wang
Journal:  Virol J       Date:  2009-09-29       Impact factor: 4.099

8.  A molecular epidemiology survey of respiratory adenoviruses circulating in children residing in Southern Palestine.

Authors:  Lina Qurei; Donald Seto; Zaidoun Salah; Maysa Azzeh
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy.

Authors:  Eliana C A Benites; Dayane P Cabrini; Andrea C B Silva; Juliana C Silva; Daniel T Catalan; Eitan N Berezin; Maria R A Cardoso; Saulo D Passos
Journal:  J Pediatr (Rio J)       Date:  2014-04-02       Impact factor: 2.197

10.  Incidence and risk factors of lower respiratory tract illnesses during infancy in a Mediterranean birth cohort.

Authors:  Carme Puig; Jordi Sunyer; Oscar Garcia-Algar; Laura Muñoz; Roberta Pacifici; Simona Pichini; Oriol Vall
Journal:  Acta Paediatr       Date:  2008-07-09       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.